The pharmaceutical world is paying close attention as the International Council for Harmonisation (ICH) releases the Step 2 draft of ICH Q1: Stability Testing of Drug Substances and Drug Products. This long-anticipated guideline is now open for public comment—and it’s set to redefine how drug stability is tested and maintained across the entire industry.
For companies relying on high-performance stability rooms—like those designed by Parameter Generation & Control and supplied by DH Lab—this is big news. Here’s what you need to know.
What Is ICH Q1—and Why Does It Matter?
Stability testing ensures that pharmaceutical products remain safe, effective, and compliant throughout their shelf life. These tests are essential for product registration, quality assurance, and lifecycle management.
Until now, pharmaceutical stability guidance has been split across multiple ICH documents (Q1A to Q1F, and Q5C). But that created confusion, overlap, and regulatory grey areas.
To resolve this, ICH has consolidated and modernised its guidance into a single document: ICH Q1.
Key objectives of the update include:
- Unifying multiple existing guidelines into one.
- Clarifying previous ambiguities.
- Modernising practices with a risk-based, science-driven approach.
- Expanding the scope to include new therapies like Advanced Therapy Medicinal Products (ATMPs).
Why This Matters for Stability Rooms
As the expectations around stability testing evolve, so too must the environments where that testing occurs. Stability rooms, like those offered by Parameter Generation & Control and distributed by DH Lab, are essential to replicating the precise environmental conditions required by regulatory bodies.
With the new ICH Q1 draft:
- Stability rooms must support a wider range of protocols—including short-term storage, in-use testing, and novel excipient assessments.
- Precision and uniformity in temperature and humidity control become even more critical as modelling and predictive stability gain prominence.
- Pharmaceutical manufacturers and R&D labs need validated, reliable environments that meet both existing and emerging guidelines.
———————————————————————————————————————–
Key Timeline for ICH Q1 Rollout
Here’s a look at how the new guideline is progressing:
- Nov 2022 – Concept paper and business plan finalised
- 2023 – Draft development, internal reviews, gap analysis
- Mar 2025 – Step 1 draft completed
- April 2025 – Step 2 draft released for public consultation (now live)
- Next steps – Public feedback will shape Step 3 and the final Step 4 document
What’s New in the ICH Q1 Draft?
The draft guideline now consolidates all previous stability-related guidance into a unified format: 18 core sections plus three annexes.
Unified Stability Framework
Say goodbye to fragmented documents like Q1A and Q1B. Everything is integrated for easier planning, execution, and review.
Updated Protocols and Requirements
New content on:
- Storage conditions
- Photostability testing
- Short-term and in-use stability
- Reference standards and novel excipients
Sections 3–7 lay out the core structure for designing and validating your stability study—making them essential reading.
Enhanced Focus Areas
New sections now cover:
- Short-term storage protocols (e.g., for temperature excursions)
- In-use testing for opened containers
- Holding time assessments for intermediates
- Stability modelling to predict shelf life and degradation patterns
There’s also a dedicated Annex for ATMPs—highlighting the need for advanced environmental control during testing of cell and gene therapies.
————————————————————————————————————————————
How to Review and Provide Feedback
If your organisation is involved in pharmaceutical development, manufacturing, or regulatory affairs, reviewing this draft is highly recommended.
Tips for submitting comments:
- Use the ICH-provided template
- Be specific—cite line numbers and suggest improvements
- Focus on clarity, feasibility, and scientific accuracy
- Avoid duplicate submissions across organisations
Future-Proof Your Stability Testing with DH Lab
As regulatory expectations evolve, stability testing environments must evolve with them. At DH Lab, we offer industry-leading Parameter Generation & Control stability rooms engineered to meet the most stringent pharmaceutical standards.
Whether you’re preparing for new ICH Q1 compliance, expanding R&D, or improving your existing testing infrastructure, our tailored stability room solutions deliver:
✅ Precise environmental control
✅ GMP-compliant performance
✅ Scalable modular design
✅ Energy efficiency and reliability
Stay Ahead of Regulatory Change
The ICH Q1 update signals a shift toward a more consistent, science-based approach to drug stability—and your testing environment needs to keep up.
Explore our range of stability rooms and walk-in chambers, or get in touch to discuss a custom solution that aligns with both your current needs and the coming regulatory landscape.
———————————————————————————————————————————————————–
For more information on our Parameter Generation and Control Stability rooms, visit us at Stability Rooms – DHLab
Visit Parameter Generation and Control at Parameter | Temperature & Humidity Chamber Manufacturer